Abstract
Background
The aims of this study were to assess the regulatory review process in South Africa from 2015 to 2017, identify the key milestones and timelines; evaluate the effectiveness of measures to ensure consistency, transparency, timeliness, and predictability in the review process; and to provide recommendations for enhanced regulatory practices.
Methods
A questionnaire was completed by the Medicines Control Council (MCC) to describe the organization of the authority, record key milestones and timelines in the review process and to identify good review practices (GRevPs).
Results
Currently, the MCC conducts a full assessment of quality, efficacy, and safety data in the review of all applications. The overall regulatory median approval time decreased by 14% in 2017 (1411 calendar days) compared with that of 2016, despite the 27% increase in the number of applications. However, the MCC has no target for overall approval time of new active substance applications and no targets for key review milestones. Guidelines, standard operating procedures, and review templates are in place, while the formal implementation of GRevPs and the application of an electronic document management system are planned for the near future.
Conclusions
As the MCC transitions to the newly established South Africa Health Products Regulatory Authority, it would be crucial for the authority to recognize the opportunities for an enhanced regulatory review and should consider models such as abridged assessment, which encompass elements of risk stratification and reliance. It is hoped that resource constraints may then be alleviated and capacity developed to meet target timelines.
Article PDF
Similar content being viewed by others
Avoid common mistakes on your manuscript.
References
Ratanawijitrasin S, Wondemagegnehu E. Effective Drug Regulation: A Multi-country Study. Geneva: World Health Organization; 2002.
Hill S, Johnson K. Emerging challenges and opportunities in drug registration and regulation in developing countries, DFID Issue Paper, 2004. http://heart-resources.org/wp-content/uploads/2012/10/Emerging-challenges-and-opportunities-in-Drug-registration-and-regulation.pdf. Accessed November 5, 2017.
Cone M, Walker S. Workshop Report: Building Quality Into Regulatory Dossiers and the Review Process: Knowing and Meeting Customer Expectations. Surrey, UK: CMR International Institute; 2005.
Cone M, McAuslane N. R&D Briefing 46: Building Quality Into Regulatory Activities: What Does It Mean? Epsom, UK: CMR International Institute, 2006.
Al-Essa R, Salek S, Walker S. An appraisal of good regulatory review practices in the Gulf Cooperation Council States. Drug Info J. 2012;46:57.
World Health Organization. Good review practice guidelines for regulatory authorities (draft for comment). 2014. http://www.who.int/biologicals/GRevPGuidelines-RHSC-endorsed-for-WHO_QAS14-576_27022014.pdf. Accessed November 5, 2017.
Soomaroo S. The Department of Trade and Industry’s involvement in the State’s procurement of ARVs. Presented to the Portfolio Committee on Economic Development, Pretoria, South Africa, 2017. https://www.thedti.gov.za/parliament/2017/Pharmaceuticals.pdf. Accessed November 3, 2017.
Medicines Control Council. Publications. http://www.mccza.com/About. Accessed October 29, 2017.
Medicines Control Council. Business Plan, 2006.
Republic of South Africa. Medicines and Related Substances Act, 1965 (Act 101 of 1965). Government Gazette 40869, May 26, 2017.
National Treasury. Guide for creating, merging, rescheduling and disestablishment of entities on the national or provincial sphere of government, 1 December 2015.
McAuslane N, Cone M, Collins J, Walker S. Emerging markets and emerging authorities: a comparative study of how key regulatory authorities in Asia, Latin America, the Middle East and Africa are developing regulatory processes and review models for new medicinal products. Drug Info J. 2009;43:349–359.
Medicines Control Council. General Guideline: Registration of Medicines, version 8, August 2012. http://www.mccza.com/documents/1d9c57df2.01_General_information_Jul12_v8_showing_changes.pdf. Accessed November 2, 2017.
Regulatory Resources for Africa. ZAZIBONA Registration Pathway, version 1, 9 June 2015. http://www.rrfa.co.za/harmonisation/. Accessed November 3, 2017.
Centre for Innovation in Regulatory Science. R&D Briefing 65: New drug approvals in six major authorities 2007-2016: Focus on the internationalisation of medicines. 2017, London.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.
About this article
Cite this article
Keyter, A., Gouws, J., Salek, S. et al. The Regulatory Review Process in South Africa: Challenges and Opportunities for a New Improved System. Ther Innov Regul Sci 52, 449–458 (2018). https://doi.org/10.1177/2168479018776649
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1177/2168479018776649